A new Korean Research Investment for Global Health Technology (RIGHT) Fund to advance innovative neglected-disease technologies
- Resource Type
- Authors
- Chang Jin Moon; In-taek Lim; Jerome H. Kim; Peter J. Hotez; Younbeen Kim; Kim Bush; Andrin Oswald; Glenn Rockman; Youngmee Jee
- Source
- PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases, Vol 14, Iss 9, p e0007956 (2020)
- Subject
- 0301 basic medicine
Economic growth
Financial Management
RC955-962
Global Health
The Republic
Medical Conditions
0302 clinical medicine
Arctic medicine. Tropical medicine
Medicine and Health Sciences
Global health
Ethnicities
Public and Occupational Health
Vaccines
Recombinant Vaccines
Neglected Diseases
Investment (macroeconomics)
Vaccination and Immunization
Socioeconomic Aspects of Health
Editorial
Infectious Diseases
Korean People
Public aspects of medicine
RA1-1270
Infectious Disease Control
Immunology
030231 tropical medicine
Biomedical Technology
Financial management
03 medical and health sciences
Asian People
Political science
Republic of Korea
Vaccine Development
Parasitic Diseases
Humans
Biomedical technology
Funding Agency
Government
business.industry
Public Health, Environmental and Occupational Health
Neglected Disease
Biology and Life Sciences
Cholera Vaccines
Health Care
030104 developmental biology
Conjugate Vaccines
People and Places
Population Groupings
Preventive Medicine
business
- Language
- ISSN
- 1935-2735
In 2018, the government of the Republic of Korea (ROK), South Korean life science companies, and a group of international funders led by the Bill & Melinda Gates Foundation launched a new and innovative funding agency to support neglected-disease research and development (R&D). The new venture is known as the Research Investment for Global Health Technology (RIGHT) Fund.